-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibrx Biosciences Publishes Presentation on Ozekibart Phase 2 Chondrosarcoma Results

PUBT·10/29/2026 19:36:20
Listen to the news
Inhibrx Biosciences Publishes Presentation on Ozekibart Phase 2 Chondrosarcoma Results
  • Inhibrx Biosciences published a presentation on secondary efficacy results from its randomized Phase 2 ChonDRAgon study of ozekibart in advanced conventional chondrosarcoma.
  • Median progression-free survival by independent review reached 5.52 months with ozekibart versus 2.66 months with placebo.
  • Disease control rates were 54% with ozekibart versus 27.5% with placebo.
  • Ozekibart delayed deterioration in pain and physical functioning compared with placebo.
  • Grade 3 or higher treatment-emergent adverse events occurred in 39% of ozekibart patients versus 25.4% receiving placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.